Cell biology

Autologous Cell Therapy Product Market to Reach USD 35.64 Billion By 2027 | Reports And Data

Retrieved on: 
Thursday, July 23, 2020

- Market Size USD 9.29 Billion in 2019, Market Growth - CAGR of 17.7%, Market Trends Rise in cardiovascular incidences

Key Points: 
  • - Market Size USD 9.29 Billion in 2019, Market Growth - CAGR of 17.7%, Market Trends Rise in cardiovascular incidences
    NEW YORK, July 23, 2020 /PRNewswire/ -- The global Autologous Cell Therapy Product Market is forecast to reach USD 35.64 billion by 2027, according to a new report by Reports and Data.
  • The global autologous cell therapy product market is anticipated to showcase an intensely competitive atmosphere in the following years.
  • North America is expected to be an active region autologous cell therapy product market over the forecast period.
  • For the purpose of this report, Reports and Data have segmented into the global autologous cell therapy product market on the basis of source, end-user, application, and region:

Draper Secures FDA Contract to Develop Acoustic Separation Technology for Manufacturing Cell Therapies

Retrieved on: 
Thursday, July 23, 2020

Under the contract, the FDA will sponsor development of a system designed to enable microfluidic acoustic cell separation and continuous, label-free purification for both autologous and allogeneic cell therapy production.

Key Points: 
  • Under the contract, the FDA will sponsor development of a system designed to enable microfluidic acoustic cell separation and continuous, label-free purification for both autologous and allogeneic cell therapy production.
  • "One of our goals is to advance the technology by constructing demonstration units, ready for commercial testing," says Fiering.
  • Draper is aiming to expand the disposable plastic cartridge, approximately the size of a cell phone, and achieve production rates of one liter an houra milestone in cell therapy manufacturing.
  • The microfluidic acoustic cell separation system is part of an integrated portfolio of technologies and resources at Draper intended to help government, industry and academia make better use of biomedicine.

BrainStorm Announces Groundbreaking Pre-Clinical Study of NurOwn® derived Exosome-Based Treatment for COVID-19 ARDS

Retrieved on: 
Thursday, July 23, 2020

COVID-19 induced pneumonia carries a high fatality rate and has been associated with acute respiratory distress syndrome (ARDS).

Key Points: 
  • COVID-19 induced pneumonia carries a high fatality rate and has been associated with acute respiratory distress syndrome (ARDS).
  • Results from a study in a mouse model of lipopolysaccharide (LPS)-induced ARDS showed that intratracheal administration of NurOwn (MSC-NTF cells) derived exosomes resulted in a statistically significant improvement in multiple lung parameters.
  • Moreover, MSC-NTF cell derived exosomes exhibited a superior effect when compared to treatment with exosomes derived from nave mesenchymal stem cells (MSC) from the same donor.
  • To-date, BrainStorm Cell Therapeutics has focused its clinical development on the application of the NurOwn technology platform to neurodegenerative disorders.

Lefamulin Demonstrates Anti-Inflammatory Activity in Pre-Clinical Study

Retrieved on: 
Thursday, July 23, 2020

The research findings reflect the first study investigating the anti-inflammatory activity of lefamulin.

Key Points: 
  • The research findings reflect the first study investigating the anti-inflammatory activity of lefamulin.
  • Importantly, lefamulin demonstrated reductions in total cell and neutrophil counts that were similar to those observed with dexamethasone at all lefamulin doses tested.
  • The anti-inflammatory effect lefamulin demonstrated in this study is very encouraging, said Jennifer Schranz, MD, Chief Medical Officer of Nabriva.
  • Complete findings of the study titled Anti-inflammatory Activity of Lefamulin in a Lipopolysaccharide-Induced Lung Neutrophilia Model is available online at: https://www.biorxiv.org/content/10.1101/2020.06.23.168393v1.full.pdf .

The global cell expansion market size is estimated to be USD 14.9 billion in 2020 and projected to reach USD 30.1 billion by 2025, at a CAGR of 15.1%

Retrieved on: 
Wednesday, July 22, 2020

The global cell expansion market size is estimated to be USD 14.9 billion in 2020 and projected to reach USD 30.1 billion by 2025, at a CAGR of 15.1%.

Key Points: 
  • The global cell expansion market size is estimated to be USD 14.9 billion in 2020 and projected to reach USD 30.1 billion by 2025, at a CAGR of 15.1%.
  • The instruments segment includes cell expansion supporting equipment, bioreactors, and automated cell expansion systems.The cell expansion supporting equipment market includes flow cytometers, cell counters and hemocytometers, centrifuges, and other supporting equipment.
  • Based on cell type, the cell expansion market is segmented into human cells and animal cells.The human cells segment includes stem cells and differentiated cells.
  • The report also provides a comprehensive review of market drivers, restraints, and opportunities in the cell expansion market.

Global 3D Cell Culture Industry Outlook, 2026 - Featuring 3D Biotek, Advanced Biomatrix, BD & Company, Corning, Kuraray Co, Lonza Group, Merck & Co, Synthecon, Thermo Fisher Scientific, and VWR

Retrieved on: 
Tuesday, July 21, 2020

The early-stage drug discovery and other related research have earned 3D cell structure increasing popularity which can be seen in its growing application.

Key Points: 
  • The early-stage drug discovery and other related research have earned 3D cell structure increasing popularity which can be seen in its growing application.
  • It has the potential to understand tissue maturation and formation, organogenesis, and cell differentiation has increased its utility.
  • The 3D cell culture market is majorly driven through the increasing usage of 3D cell culture in diagnostic centers, hospitals, pharmaceutical, and biotech companies.
  • The report also contains insight regarding technological innovations and advanced solutions for the 3D Cell Culture.

Agenus To Participate in a Panel on Cell Therapy for Infectious Diseases at the B. Riley Virtual Infectious Disease Summit

Retrieved on: 
Tuesday, July 21, 2020

Title: Pursuing Curative Cell Therapy Approaches Cell Therapy has become a fast-changing field after becoming a powerful clinical therapy for late line cancer patients with the approval of the first generation CD19+ CAR T cell treatments (Yescarta and Kymriah).

Key Points: 
  • Title: Pursuing Curative Cell Therapy Approaches Cell Therapy has become a fast-changing field after becoming a powerful clinical therapy for late line cancer patients with the approval of the first generation CD19+ CAR T cell treatments (Yescarta and Kymriah).
  • AgenTus also aims to advance adoptive cell therapy formats which would enable off-the-shelf living drugs.
  • Agenus is a clinical-stage immuno-oncology company focused on the discovery and development of therapies that engage the body's immune system to fight cancer and infections.
  • Information that may be important to investors will be routinely posted on our website and twitter.

Gamida Cell Announces Appointment of Michele Korfin as Chief Operating and Chief Commercial Officer

Retrieved on: 
Tuesday, July 21, 2020

Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to finding cures for blood cancers and serious blood diseases, today announced the appointment of Michele Korfin as chief operating and chief commercial officer.

Key Points: 
  • Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to finding cures for blood cancers and serious blood diseases, today announced the appointment of Michele Korfin as chief operating and chief commercial officer.
  • Im delighted to welcome Michele to Gamida Cell, stated Julian Adams, Ph.D., chief executive officer at Gamida Cell.
  • I am excited to join the Gamida Cell team at such a promising and important time in the companys history.
  • Prior to joining Gamida Cell, Ms. Korfin served as chief operating officer at TYME Technologies.

R3 International Offering New Program for Stem Cell Therapy for Degenerative Disc in Mexico

Retrieved on: 
Tuesday, July 21, 2020

SCOTTSDALE, Ariz., July 21, 2020 /PRNewswire-PRWeb/ --R3 International is now offering a new program for stem cell therapy for degenerative disc disease in Mexico .

Key Points: 
  • SCOTTSDALE, Ariz., July 21, 2020 /PRNewswire-PRWeb/ --R3 International is now offering a new program for stem cell therapy for degenerative disc disease in Mexico .
  • The back pain program starts with a free phone consultation with an R3 licensed, experienced stem cell doctor.
  • R3 provides travel from the San Diego airport to the stem cell clinic in Mexico, which is only 20 minutes away.
  • In addition to treating degenerative disc disease, R3 also offers stem cell treatment for knees , hips, shoulders, post-stroke, RA, MS, ALS, Lyme, kidney failure and more.

Notch Therapeutics Appoints David Main as President and Chief Executive Officer to Advance the Company's Novel Gene-Edited, iPSC-Derived Immune Cell Therapeutics

Retrieved on: 
Monday, July 20, 2020

TORONTO, July 20, 2020 /PRNewswire/ --Notch Therapeutics Inc., a biotechnology company creating universally compatible, off-the-shelf T cell therapies for cancer and immune disorders from renewable stem cell sources, is pleased to announce the appointment of David Main as President and Chief Executive Officer.

Key Points: 
  • TORONTO, July 20, 2020 /PRNewswire/ --Notch Therapeutics Inc., a biotechnology company creating universally compatible, off-the-shelf T cell therapies for cancer and immune disorders from renewable stem cell sources, is pleased to announce the appointment of David Main as President and Chief Executive Officer.
  • Notch is applying its scalable Engineered Thymic Niche (ETN) technology platform to develop homogeneous and universally compatible, stem cell-derived T cell therapies.
  • Prior to his leadership of Aquinox, Mr. Main served as President and CEO of INEX Pharmaceuticals and as a Vice President of QLT.
  • Notch is an immune cell therapy company creating universally compatible, allogeneic (off-the-shelf) T cell therapies for the treatment of cancer and immune disorders.